Probiotic, Prebiotic, and Brain Development by Cerdó, Tomás et al.
nutrients
Review
Probiotic, Prebiotic, and Brain Development
Tomás Cerdó 1,2, Alicia Ruíz 2,3, Antonio Suárez 3 and Cristina Campoy 1,2,4,5,* ID
1 Department of Paediatrics, School of Medicine, University of Granada, 18016 Granada, Spain; tcr@ugr.es
2 EURISTIKOS Excellence Centre for Paediatric Research, Biomedical Research Centre, University of Granada,
18016 Granada, Spain; aliruizrodriguez@ugr.es
3 Department of Biochemistry and Molecular Biology 2, Biomedical Research Centre, University of Granada,
18016 Granada, Spain; asuarez@ugr.es
4 Spanish Network of Biomedical Research in Epidemiology and Public Health (CIBERESP),
Carlos III Institute, 18016 Granada, Spain
5 Department of Paediatrics, Faculty of Medicine, University of Granada, Av. de la Investigación, 11,
18016 Granada, Spain
* Correspondence: ccampoy@ugr.es; Tel.: +34-629-308-695
Received: 8 September 2017; Accepted: 10 November 2017; Published: 14 November 2017
Abstract: Recently, a number of studies have demonstrated the existence of a link between the
emotional and cognitive centres of the brain and peripheral functions through the bi-directional
interaction between the central nervous system and the enteric nervous system. Therefore, the use of
bacteria as therapeutics has attracted much interest. Recent research has found that there are a variety
of mechanisms by which bacteria can signal to the brain and influence several processes in relation to
neurotransmission, neurogenesis, and behaviour. Data derived from both in vitro experiments and
in vivo clinical trials have supported some of these new health implications. While recent molecular
advancement has provided strong indications to support and justify the role of the gut microbiota
on the gut–brain axis, it is still not clear whether manipulations through probiotics and prebiotics
administration could be beneficial in the treatment of neurological problems. The understanding of
the gut microbiota and its activities is essential for the generation of future personalized healthcare
strategies. Here, we explore and summarize the potential beneficial effects of probiotics and prebiotics
in the neurodevelopmental process and in the prevention and treatment of certain neurological human
diseases, highlighting current and future perspectives in this topic.
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1. Introduction
The micro-organisms that inhabit the human gastrointestinal tract (GI) have been implicated in
the development and functioning of a number of basic physiological processes, such as digestion,
immunity, and the maintenance of homeostasis. The GI microbiota may also play a role in multiple
diseases, ranging from inflammation to obesity [1,2]. Recently, many studies have shown that gut
microbiota play a very important role in the development and function of the central nervous system
(CNS) through specific channels, such as metabolic, neuroendocrine, and immune pathways [3].
In particular, these researchers have found bi-directional communication between the brain and the
gut microbiota, denominated the microbiota–gut–brain axis [4–6].
Although the molecular mechanisms by which the gut microbiota communicate with the brain
are not yet clear, the link between both components is currently attributed to immune signals and
the vagus nerve. Cellular components produced by gut microbiota, such as lipopolysaccharide (LPS),
peptidoglycan, and flagellin, are recognized by pattern-recognition receptors (PRRs), such as Toll-like
receptors (TLRs), NOD-like receptors (NLRs), or RIG-1-like receptors (RLRs), on epithelial and immune
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cells, producing cytokines, hormones, and other molecular signals, which will act as neurotransmitters
within the CNS [7]. Several studies have found that, in the densely innervated gut, the vagus nerve is
involved in the bi-directional communication of the microbiota–gut–brain axis [8,9], while others have
shown vagus-independent effects [10,11]. Either way, a supplementing nutrition therapy with specific
probiotic commensals and prebiotics can alter the excitability of enteric nervous system (ENS) sensory
neurons [12–14]. Prebiotics-induced growth of probiotic members within the Bifidobacterium and
Lactobacillus genera show multiple beneficial effects on host immunity and physiology [15]. Moreover,
strong effects of Bifidobacterium and Lactobacillus spp. on the brain–gut axis have been reported [16].
This review summarizes current knowledge on the influence of the establishment of the gut
microbiota in critical neurodevelopmental windows, and discusses recent findings on the interactions
between the gut microbiota and the host’s brain–gut axis communications. In addition, current research
on the effects of the administration of probiotics and prebiotics in specific neurological disorders is
reviewed. Finally, recommendations for future research on this topic are also discussed.
2. Establishment of Intestinal Microbiota during Early Neurodevelopmental Windows
Gut microbiota establish a beneficial cohabitation with the host that will prime for health later in
life [17]. The assembly of the gut microbiota occurs during the first three years of life, starting from birth,
where there is a rapid rate of colonization and expansion of gut bacteria dominated by Actinobacteria
and Proteobacteria that shifts towards one dominated by Firmicutes and Bacteroidetes, increasing
compositional diversity and stability while maturing into an adult-like state [18]. This process
coincides in time with the intense synaptogenesis and pruning in the cerebral cortex during early
life [18–20], ending in adolescence [21]. Therefore, perturbations of gut microbiota colonization
and maturation by environmental factors may influence brain development. The dynamics of the
microbial ecosystem’s maturation during this critical period of CNS development is influenced by
several environmental factors, such as mother-to-child bacterial transfer, mode of delivery, and type of
feeding. The mother-to-child transfer of commensal bacteria in the uterus has been shown to influence
an infant’s immune system development [22,23]. Until recently, the idea that foetuses were sterile in
the uterus and that the microbial colonization of the new-born started during and after birth had been
widely accepted [24]. However, nowadays, this belief has been challenged by evidence of microbes
in placenta and other tissues surrounding the foetus, such as umbilical cord blood after vaginal and
caesarean birth [25–27]. Several studies have analysed the meconium of new-born babies and showed
the presence of bacterial populations, including Enterococcus, Lactococcus, Escherichia, Leuconostoc,
and Streptococcus, though at low levels, concluding that gut colonization occurs mainly after birth [28].
Based on these findings, prenatal probiotic intervention has been shown to modulate the expression
of TLR-related genes in the placenta and foetal GI tract and to reduce atopic dermatitis [29,30].
Thus, prenatal and postnatal maternal oral probiotic therapy may represent an effective method of
intervention to prevent pathologies such as allergy [31], atopic diseases [32], and neurodevelopmental
disorders, reviewed below. Still, the origin of the microbiota colonizing the placenta is unknown and
results have to be carefully interpreted, because, in samples with low microbial biomass, such as those
from placenta, the risk of contamination is high when using high-throughput sequencing methods
based on DNA amplification [29]. Further studies are needed to discern whether foetuses have contact
with bacteria before birth or are colonized during and after parturition.
Regardless of mother-to-child transmission within the intrauterine environment, two different
modes of maternal–infant transmission during delivery have been proposed: (a) horizontal, in which
microbes are taken up from the environment for infants born by caesarean section; and (b) vertical,
in which vaginal microbes are transferred during parturition to the infants [33]. Infants delivered
by Caesarean section are more likely to suffer several diseases, such as asthma, obesity, or allergies,
in adulthood [34]. Interestingly, a study carried out by Jasarevic et al. using a mouse model of
early prenatal stress found that changes in the vaginal microbiome were associated with shifts
in the abundance of Lactobacillus in the expression of maternal stress proteins related to vaginal
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immunity, in offspring metabolic profiles related to energy balance, and in the amino acid profiles of
the developing brain [35].
The third strong environmental factor that influences an infant’s gut microbial development as
well as neurodevelopment is the type of feeding. In recent years, several studies have reported that
breastfeeding and particularly full breastfeeding has beneficial effects on child neuropsychological
development [36]. Human milk is the optimal feeding source, since it provides all the nutrition factors
that an infant needs for healthy development. Human milk is not sterile, and, during breastfeeding,
bacteria from mother’s skin and mammary gland via maternal dendritic cells and macrophages [37]
are transferred to the baby [38]. Breast-fed infants tend to contain a more uniform population of gut
microbes dominated by Bifidobacterium and Lactobacillus [39], whereas formula-fed infants exhibit
higher proportions of Bacteroides, Clostridium, Streptococcus, Enterobacteria, and Veillonella spp. [21].
Bacteria belonging to the Bifidobacterium genus present in human milk are early colonizers that
characterize the gut microbial composition of healthy breast-fed new-born’s [40] with beneficial
functions for the host, such as the acceleration of the maturation of the immune response, the limitation
of excessive inflammation, the improvement of the intestinal permeability, and an increase of acetate
production [41]. In mice, B. infantis produces antidepressant-like effects and normalizes peripheral
pro-inflammatory cytokine and tryptophan concentrations, both of which have been implicated in
depression [42–44]. Moreover, breastfeeding has an additional role in the establishment of an infant’s
gut microbiota, since it contains bioactive molecules that are increasingly recognized as drivers of
microbiota development and overall gut health [45]. Among the nutrients present in human milk,
oligosaccharides constitute the third-most abundant class of molecules in terms of concentration after
lactose and lipids. Nowadays, more than 200 different structures have been identified as human milk
oligosaccharides (HMOs) [35]. HMOs can act as prebiotics, stimulating the growth of specific bacterial
groups such as Staphylococci [46] and Bifidobacteria [47].
These results suggest that postnatal neurodevelopment and gut microbiota establishment co-occur,
suggesting the intriguing possibility of a bi-directional regulation of each other’s maturation [48].
Further studies are needed in order to clarify whether those differences in bacterial acquisition during
early life lead to neurodevelopmental differences in infants.
3. Gut Microbiota–Brain Axis
The brain and the gut reciprocally influence each other by constant communication
(Figure 1). The brain–gut–microbiota axis includes the CNS, the endocrine-immune system,
the hypothalamus–pituitary–adrenal (HPA) axis, the autonomic nervous system, the ENS, and the
gut microbiota [49]. This bi-directional communication enables signalling from the brain to influence
motor, sensory, and secretory modalities of the GI tract, and conversely, signalling from the gut to affect
brain function, most notably the hypothalamus and amygdala that are implicated in stress [50–52].
Though communication between brain and gut was realized in the middle of the nineteenth
century [53], gut microorganisms had not been considered important for the development and
function of the CNS or for brain diseases until recently, expanding the term to microbiome–gut–brain
axis [54]. In humans, evidence of microbiome–gut–brain axis interactions have been obtained from the
association of shifts in gut microbiota composition with central nervous disorders (i.e., autism spectrum
disorder (ASD) and anxiety and depressive behaviours) and functional gastrointestinal disorders [54].
Most of the data demonstrating the role of the microbiota in the gut–brain axis have been obtained from
germ-free animals [55]. Mice fed with prebiotics showed diminished stressor-induced anxiety-like
behavior [56]. In a mouse model of ASD, Buffington et al. showed that a maternal high-fat diet
reduced the number of oxytocin immunoreactive neurons in the hypothalamus and induced dysbiosis
that was restored by a commensal Lactobacillus reuteri strain [57]. In a mouse model of Parkinson’s
disease, Sampson et al. highlighted a negative interaction in the microbiome–gut–brain axis because
the absence of gut bacteria decreased aggregated misfolded α-synuclein levels and reduced the
severity of the animals’ abnormal movements. The authors showed that short chain fatty acids
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(SCFA), such as acetate, propionate, and butyrate, the end products of anaerobic fermentation of
dietary fibre and starch, promoted a microglia-mediated immune response and increased α-synuclein
aggregation, causing movement abnormalities [58]. Butyrate can cross the blood-brain barrier (BBB)
and produce a dose-dependent increase in neuronal and glial nuclear histone H3 acetylation in mice
due to its potential to inhibit histone deacetylation [59]. Another metabolite whose levels in the host
are influenced by gut microbiota is tryptophan, the amino acid precursor of the neurotransmitter
serotonin, and kynurenine, the main breakdown product of tryptophan catabolism [60]. Kynurenine
intake during gestation and postnatal development, a time frame in which the maternal and offspring
microbiota undergo major compositional and functional remodelling, produced neurochemical and
cognitive deficits later in adulthood [61]. The prenatal inhibition of kynurenine synthesis modified
hippocampal neuron morphology and changed neocortical and cerebellar protein expression that
persisted into adulthood. In germ-free and in antibiotic-induced microbiota-depleted mice, despite
increased circulating tryptophan levels, serotonin and kynurenin availabilities were decreased,
suggesting that gut microbiota modulated kynurenin metabolism [62]. Distinct gut microbial species
affect host physiology, producing diverse neuromolecules involved in mood regulation. Lactobacillus
and Bifidobacterium spp. generate gamma-aminobutyric acid (GABA). Candida, Streptococcus, Escherichia,
and Enterococcus spp. synthesise serotonin while Bacillus spp. produces dopamine [63].
Gut microbiota also influence the regulation of BBB integrity. The BBB is an active interface
between systemic circulation and the CNS that maintains brain homeostasis by preventing the entry
of potentially toxic or harmful substances and regulates the transport of nutrients and the removal
of metabolites [64]. Braniste et al. (2014) [65] showed that the transplantation of gut microbiota into
germ-free mice normalized BBB permeability and upregulated the expression of tight junction proteins.
Therefore, gut microbiota have a key role in regulating BBB permeability, suggesting that the maternal
gut microbiome influences an offspring’s BBB integrity. Together with the results discussed in the
previous section, these findings open an intriguing question on the mechanism by which a mother’s
gut microbiota cooperate in regulating BBB integrity and ultimately brain function development.
Gut microbiota have direct effects on the immune system, which constitutes another route of
communication between gut microbes and the brain. The signalling molecules of the immune system,
cytokines and chemokines, access the brain from the periphery via the vagus nerve or directly via
the circumventricular organs [66]. The administration of rifaximin (a non-systemic, broad-spectrum
antibiotic) to stressed rats increased the abundance of Lactobacillus in the ileum and the expression of
the tight junction protein occludin while decreasing the expression of pro-inflammatory interleukin 17,
interleukin 6, and tumour necrosis factor α mRNA [67].
Since many of the above effects have been observed during early life, it is plausible that
an environmentally induced dysbiosis of infants’ microbiota (e.g., mode of birth, maternal transmission
of a suboptimal microbiota, antibiotics) may generate altered patterns of microbial metabolites
with detrimental effects in human CNS development. Further research is needed to unravel these
mechanisms and develop probiotics or prebiotics therapies that shape gut microbial composition and
metabolism to ultimately modulate CNS development.
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Figure 1. The gut microbiota–brain axis. The central part of the figure shows the bidirectional 
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influences of prebiotics and probiotics on human diseases. The right side of the figure shows the 
consequences of gut dysbiosis/homeostasis. Intestinal dysbiosis can adversely influence gut 
physiology, leading to inappropriate brain–gut axis signalling and associated consequences for CNS 
functions and disease states. Abbreviations: Non-Alcoholic Fatty Liver Disease (NAFLD), 
Inflammatory Bowel Disease (IBD), Attention deficit hyperactivity disorder (ADHD), Autism 
spectrum disorder (ASD). 
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In 2001, the Food and Agriculture Organization of the United Nations and the World Health 
Organization (FAO/WHO) proposed the following definition of probiotics: “live micro-organisms 
which, when administered in adequate amounts, confer a health benefit on the host” [68], which was 
reaffirmed in 2014 [69]. Probiotics, comprised by strains of Lactobacilli, Bifidobacteria and 
Saccharomycetes have been suggested to play a role in fighting human diseases, such as non-alcoholic 
fatty liver disease (NAFLD), allergy diseases, and asthma. They also promote protection against 
atopic disease in the infant during pregnancy and breastfeeding [32,70,71]. In addition, probiotics 
also reduce the duration of antibiotic therapy, and reduce symptom severity in immune-related 
diseases, such as inflammatory bowel diseases (IBDs), celiac disease, metabolic syndrome and 
diabetes [72,73]. 
The search for probiotics that can affect cognitive functions, known as psychobiotics, has 
increased in recent years (Table 1). Psychobiotics are defined as live organisms that, when ingested 
in adequate amounts, produce beneficial health effects to patients suffering from psychiatric illness 
[74]. Depression is currently a major psychiatric disorder in developed countries, and is 
characterized by a low mood or loss of interest and anxiety affecting appetite and sleep. Messaoudi 
et al. [75,76] reported a double-blind, placebo-controlled, randomized study where a multispecies 
probiotic containing Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) was 
administered to healthy women for 30 days. This treatment resulted in a decrease in the global 
scores of the hospital anxiety and depression scale (HADs) and the global severity index of the 
Hopkins symptoms checklist (HSCL-90) due to the decrease of the sub-scores of somatization, 
depression, and anger–hostility spheres. In a cohort of 124 healthy humans, Benton et al. reported 
that the consumption of Lactobacillus casei-containing yogurt improved the self-reported mood of 
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initially poor [77]. Similarly, Steenbergen et al. reported a significantly reduced overall cognitive
reactivity to depression, in particular aggressive and ruminative thoughts, in forty healthy young adults
that consumed either a probiotic supplement or placebo for 4 weeks [78]. Recently, Akkasheh et al.
showed that the consumption of a probiotic supplement significantly decreased Beck Depression
Inventory (BDI) scores, indicating overall improved symptoms, including mood, in 40 patients
diagnosed with depression [79]. Conversely, Marcos et al. reported that probiotics decreased,
respectively, levels of stress and anxiety assessed using the state-trait anxiety inventory (STAI) that
remained unchanged in subjects under academic examination stress [80]. In a recent study carried
out by Romijn et al. [81], administering a multispecies probiotic containing L. helveticus and B. longum
in 79 participants that were not taking psychotropic medications at that moment and with at least
moderate scores on self-report mood measures, found no evidence that the probiotic formulation was
effective in treating low mood or in moderating the levels of inflammatory and other biomarkers.
Improved cognitive function (neuropsychological and cognitive fatigue) was reported by Chung et al.,
which tested a L. helveticus-fermented milk in healthy 60–75 year olds, though no effects on stress or
geriatric depression symptoms were observed [82].
Probiotics affect mood by their ability to modulate pain in the gut. A recent study reported
that the administration of Lactobacillus reuteri DSM 17938 in the treatment of children with functional
abdominal pain (FAP) and irritable bowel syndrome (IBS) is associated with a possible reduction
of the intensity of pain [83]. In 35 patients suffering from chronic fatigue syndrome, Rao et al.
showed that while the consumption of the probiotic improved anxiety scores, it had no effect
on depressive symptoms [84]. Giannetti et al. also reported that a probiotic mixture of B. infantis
M-63, B. breve M-16V, and B longum BB536 was associated with improvement in children with IBS,
but not in children with functional dyspepsia (FD) [85]. In healthy women without gastrointestinal
or psychiatric symptoms, the consumption of a fermented milk product containing B. animalis subsp.
lactis, Streptococcus thermophilus, Lactobacillus bulgaricus, and L. lactis subsp. lactis resulted in robust
alterations in activity in the brain regions that control the central processing of emotions and sensations,
as observed by functional magnetic resonance imaging [86].
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Table 1. Studies evaluating probiotics supplementation on central nervous system (CNS) disorders.
Study (Reference) Cohort Population Probiotic Used Key Findings
Messaoudi et al. (2011) [75,76]
55 healthy human volunteers plus 25 subjects with
urinary free cortisol (UFC) levels less than
50 ng/mL (less stressed subjects), 10 subjects
received the probiotic and 15 placebo.
Lactobacillus helveticus R0052 and Bifidobacterium longum
R0175 (PF)
Beneficial effects on anxiety and depression related behaviors
in healthy human volunteers and volunteers with lower levels
of cortisol
Benton et al. (2007) [77]
124 healthy adults volunteers were randomly
allocated to a group that consumed, on a daily basis,
a probiotic-containing milk drink or a placebo
Lactobacillus casei Shirota
The consumption of a probiotic-containing yoghurt improved
the mood of those whose mood was initially poor. However,
there was not an increased frequency of defaecation.
Steenbergen et al. (2015) [78]
40 healthy young adults were randomly assigned to
receive a 4-week intervention of either placebo or
multispecies probiotics in a triple-blind intervention
assessment design.
Bifidobacterium bifidum W23, Bifidobacterium lactis W52,
Lactobacillus acidophilus W37, Lactobacillus brevis W63,
Lactobacillus casei W56, Lactobacillus salivarius W24,
and Lactococcus lactis (W19 and W58)
Participants who received multispecies probiotics showed
a significantly reduced overall cognitive reactivity to sad mood,
which was largely accounted for by reduced rumination and
aggressive thoughts.
Akkasheh et al. (2016) [79]
40 patients with a diagnosis of major depressive
disorder (MDD) whose age ranged between 20 and
55 years were randomized.
Lactobacillus acidophilus, Lactobacillus casei,
and Bifidobacterium bifidum.
Patients who received probiotic supplements had significantly
decreased Beck Depression Inventory total scores
Marcos et al. (2004) [80] 136 university students were randomized.
Lactobacillus delbrueckii subsp. bulgaricus and
Streptococcus salivarius subsp. thermophilus plus
Lactobacillus casei DN-114001
There was no significant treatment effect on anxiety.
Romijn et al. (2017) [81]
79 participants not currently taking psychotropic
medications with at least moderate scores on
self-report mood measures. Participants were
randomly allocated to receive a probiotic
preparation or placebo.
Lactobacillus helveticus and Bifidobacterium longum No significant difference was found between the probiotic andplacebo groups on any psychological outcome measured.
Jadrešin et al. (2017) [83]
55 children with age between 4 and 18 years old,
diagnosed as functional abdominal pain (FAP) or
irritable bowel syndrome (IBS) were
randomly allocated.
Lactobacillus reuteri DSM 17938
Administration of L. reuteri DSM 17938 was associated with
a possible reduction of the intensity of pain and significantly
more days without pain in children with FAP and IBS
Giannetti et al. (2016) [85]
48 children with IBS aged between 8 and 17.9 years
and 25 with functional dyspepsia (FD) with age
between 8 and 16.6 years were randomized.
Bifidobacterium infantis M-63, breve M-16V,
and longum BB536
In children with IBS a mixture of Bifidobacteria is associated with
improvement in abdominal pain (AP) and quality of life (QoL).
Kałużna-Czaplińska et al.
(2012) [87] 22 autistic children. Lactobacillus acidophilus
The probiotic supplementation let to a significant decrease in
D-arabinitol (DA) and the ratio of D-/L-arabinitol (DA/LA)
and to a significant improvement in ability of concentration
and carrying out orders
West et al. (2013) [88] 33 ASD children.
Delpro® (Lactocillus acidophilus, Lactobacillus casei,
Lactobacillus delbruecki, Bifidobacteria longum,
Bifidobacteria bifidum)
88% reported a decrease in total autism treatment evaluation
checklist (ATEC) score, an improvement of ASD symptoms.
Participants also had significant improvements in all ATEC
domains (speech/language/communication, sociability,
sensory/cognitive awareness, and health/physical/behavior)
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Table 1. Cont.
Study (Reference) Cohort Population Probiotic Used Key Findings
Tomova et al. (2015) [89] 10 children with autism, 9 siblings and10 healthy children.
“Children Dophilus” containing three strains of
Lactobacillus (60%), two strains of Bifidobacterium (25%),
and one strain of Streptococcus (15%)
Probiotic diet supplementation normalized the
Bacteroidetes/Firmicutes ratio, Desulfovibrio spp. and the amount
of Bifidobacterium spp. in feces of autistic children.
No significant difference was found to reduce symptom
severity in patients with autism.
Santocchi et al. (2016) [90]
100 preschoolers with ASD on the basis of
a symptom severity index specific to
gastrointestinal (GI) disorders. Patients with and
without GI disorders were blind randomized to
regular diet with probiotics or with placebo
“Vivomixx®” (one strain of Streptococcus thermophilus
DSM 24731, three strains of Bifidobacterium
(Bifidobacterium breve DSM 24732, B. longum DSM 24736,
B. infantis DSM 24737), and four strains of Lactobacillus
(Lactobacillus acidophilus DSM 24735, Lactobacillus
plantarum DSM 24730, Lactobacillus paracasei DSM 24733,
Lactobacillus delbrueckii subsp. bulgaricus DSM 24734))
Ongoing study
Dickerson et al. (2014) [91] and
Tomasik et al. (2015) [92]
32 patients healthy and 33 patients with
schizophrenia meeting DSM-IV criteria and with at
least moderately severe psychotic symptoms
Lactobacillus rhamnosus strain GG and Bifidobacterium
animalis subsp. lactis strain Bb12
No significant difference was found to reduce symptom
severity in patients with schizophrenia. Probiotic regulate
immune and intestinal epithelial cells through the IL-17 family
of cytokines
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Probiotics have been tested to normalize gut microbial composition and metabolism, enhance
gut barrier, and relieve patients suffering from ASD. In 2012, Kaluzna-Czaplinska and Blaszczyk
reported that the administration of Lactobacillus acidophilus in 22 ASD subjects decreased D-arabinitol
concentration and the ratio of D-arabinitol to L-arabinitol in urine, and improved their ability
to follow directions, as demonstrated through a comparison with data collected before the
treatment [87]. Another study reported that a combination of Lactobacillus acidophilus, L. casei,
Lactobacillus delbrueckii, B. longum and Bifidobacterium bifidum, formulated with the imunomodulator
Del-Immune V (Lactobacillus rhamnosus V lysate), decreased the severity of ASD symptoms and
improved GI symptoms in 33 children [88]. Moreover, a recent study of “Children Dophilus”
(a combination of three species of Lactobacillus, two species of Bifidobacterium and one strain of
Streptococcus) in 10 ASD children showed higher GI dysfunction in ASD children and siblings and
a very strong association of the amount of Desulfovibrio spp. with the severity of autism. After the
intervention, the Bacteroidetes/Firmicutes ratio, Desulfovibrio spp., and the amount of Bifidobacterium
spp. were normalized in faeces of autistic children [89]. However, the effects of treatments with
probiotics on children with ASD need to be evaluated through rigorous, controlled trials. In a recent
clinical study currently in progress, Santocchi et al. are providing a multispecies probiotic (one strain
of S. thermophilus DSM 24731, three strains of Bifidobacterium (B. breve DSM 24732, B. longum
DSM 24736, and B. infantis DSM 24737), and four strains of Lactobacillus (L. acidophilus DSM 24735,
Lactobacillus plantarum DSM 24730, Lactobacillus paracasei DSM 24733, and L. delbrueckii subsp. bulgaricus
DSM 24734) to a group of 100 pre-schoolers with ASD. This study will try to provide new insights to
clinical and neurophysiological patterns in response to a probiotic mixture in ASD patients [90].
Probiotics are also tested in the treatment of schizophrenia and bipolar disorder. One of the first
trials of probiotic compounds in schizophrenia used a combined probiotic of L. rhammosus strain GG
and B. animals subsp. Lactis strain Bb12. The results showed no significant difference in psychiatric
symptom severity between probiotic and placebo supplementation [91]. However, other studies
have found that probiotic supplementation significantly alters the levels of several serum proteins,
including the von Willebrand factor and the brain-derived neurotrophic factor, and lowered the level
of antibodies to the fungus Candida albicans [92,93].
Despite that the majority of the studies found positive results on symptoms in these neurological
disorders, future studies are needed to identify potential probiotics for the effective modulation of
these disorders as well as to define probiotics risk in therapeutic interventions. Gut microbial studies
that use 16S rRNA gene sequencing to characterize bacteria must consider that highly similar bacteria
(higher than 97% sequence identity) can have large differences in genomic sequences and profound
differences in growth and metabolism. Hence, it is important to characterize probiotics to the strain
level and apply next-generation sequencing techniques to analyse the functions encoded by their
genome [94]. Therefore, the effects of one probiotic strain should not be generalized to others without
confirmation in separate studies.
5. Prebiotics
Although the concept of a prebiotic was first defined in 1995 by Gibson, the current definition of
a prebiotic is the one proposed by the International Scientific Association for Probiotics and Prebiotics
(ISAPP): a substrate that is selectively utilized by host micro-organisms and confers a health benefit [95].
The group of substances recognized for their ability to influence gastrointestinal health comprise
certain non-digestible oligosaccharides (NDOs), soluble fermentable fibres, and HMOs. NDOs are
low molecular weight carbohydrates in nature that are intermediates between simple sugars and
polysaccharides. The use of NDOs as prebiotics has rapidly increased because the enrichment of a diet
with NDOs provides the opportunity to improve the gut microbial ecosystem, including bacterial
populations, biochemical profiles, and physiological effects [96]. Fibre influences satiety by the
following two mechanisms. One is by increasing the chewing time of fibre-rich foods, which promotes
saliva and gastric acid production and increases gastric distension, triggering afferent vagal signals of
Nutrients 2017, 9, 1247 10 of 19
fullness contributing to this end. The other mechanism is by slowing gastric emptying and decreasing
the rate of glucose absorption in the small intestine. Consequently, the insulin response may also be
attenuated; this is sometimes correlated with satiation and satiety [97]. Various hormones (i.e., ghrelin,
the polypeptide YY, and the glucagon-like peptide) have been related to satiety, and are sent to the
brain, where they regulate food intake and overall energy balance [98].
Though prebiotic therapies potentially could be beneficial for children with a genetic
pre-disposition to develop ASD or attention deficit hyperactivity disorder because of their selective
enhancement of Lactobacilli and Bifidobacteria growth [99], a small number of studies has examined
the effect of these prebiotics on disorders related to CNS (Table 2). Inductive evidence that prebiotics
modulated emotional satisfaction was provided by Hume et al., who investigated the effect of
oligofructose-enriched inulin/d administration versus a placebo (maltodextrin) in a randomized,
double-blind, placebo-controlled trial with 42 children (who were aged 7–12 and were overweight and
obese) [100]. Prebiotic supplementation improved subjective appetite ratings, reducing energy intake
in older but not in younger children.
In a cohort of healthy male and female subjects (n = 45), Schmidt et al. tested the intake of
fructo-oligosaccharides (FOS) and Bimuno®-galactooligosaccharides (B-GOS), and reported that only
B-GOS reduced the waking-cortisol response [101]. Exaggerated waking cortisol is a biomarker of
emotional disturbances, such as depression [102]. Besides this, the subjects also provided measures
of vigilance, or attention to negative stimuli, which is also a behavioral marker of anxiety and
depression [103]. B-GOS attenuated vigilance, suggesting a reduction in anxiety and depression [104].
Van den berg et al. found no evidence that the use of short-chain galacto-oligosaccharides/long-chain
fructo-oligosaccharides/pectin-derived acidic oligosaccharides in preterm infants at 24 months
improves neurodevelopmental outcomes [105]. LeCouffe et al. studied the effect of an enteral
supplementation of a prebiotic mixture (neutral and acidic oligosaccharides) in the neonatal period
and found no effect on neurodevelopment [106], though lower Bifidobacteria counts are associated with
serious neonatal infections and lower neurodevelopmental outcomes.
More studies are required to determine whether prebiotics exert a beneficial effect on
neurodevelopmental disorders in infants, and to understand the mechanism of action, by stimulating
certain bacterial taxa or bacterial activities within gut microbiota. Efficacy, safety, and dosing schedules
should be established for each prebiotic product in long-term follow-up studies.
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Table 2. Studies evaluating prebiotics and synbiotics supplementation on CNS disorders.
Study (Reference) Cohort Population Prebiotic Used Key Findings
Prebiotics
Hume et al. (2017) [100] 42 boys and girls, ages 7–12 years, with a bodymass index (BMI) of ≥85th percentile Oligofructose-enriched inulin/d
Prebiotic supplementation in children with overweight and obesity
significantly increased feelings of fullness and reduced prospective
food consumption in older but not in younger children
Schmidt et al. (2105) [101] 45 adults healthy volunteers FOS and Bimuno®-galactooligosaccharides, B-GOS
B-GOS reduced waking-cortisol response and decreased
attentional vigilance to negative versus positive information
van den Berg et al. (2016) [105]
77 preterm infants (gestational age <32 weeks
and/or birth weight <1500 g), admitted to the
level-III neonatal intensive care unit (NICU)
scGOS/lcFOS/pAOS
Neurodevelopmental outcomes were not different in the
scGOS/lcFOS/pAOS and placebo group. Infections, lower
bifidobacteria counts, and higher serum cytokine levels during the
neonatal period were associated with lower neurodevelopmental
outcomes at 24 months of age
LeCouffe et al. (2014) [106]
93 Infants, with a gestational age (GA) of less
than 32 weeks and/or birth weight of less than
1500 g, participed in the study (prebiotic mixture
group (n = 48) and placebo group (n = 45)
80% scGOS/lcFOS and 20% pAO
Short-term enteral supplementation of a prebiotic mixture in the
neonatal period had no effect on neurodevelopmental outcome in
preterm infants in the first year of life
Synbiotics
Malaguarnera et al. (2007) [107] 60 cirrhotic patients (30 with synbiotics and30 with placebo) Bifidobacterium longum plus fructo-oligosaccharides
Patients with minimal hepatic encephalopathy (MHE) treated with
Bifidobacterium + FOS, showed an improvement and a recovery of
neuropsychological activities related to short-term memory,
attention and computing ability, language, orientation ability,
and cognitive activities
Firmansyah et al. (2011) [108] 393 healthy 12 month-old toddlers
The probiotic Bifidobacterium longum BL999 (ATCC: BAA
999) and Lactobacillus rhamonosus, LPR (CGMCC 1.3724),
the prebiotics inulin (30%) and fructo-oligosaccharide
(70%), and the LCPUFA, arachidonic acid (AA) and
docosahexaenoic acid (DHA)
Changes in cognitive and adaptive behaviour scores between
12 and 16 months were higher but not significantly different in the
synbiotics group compared with the control group
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6. Synbiotics
The term synbiotic was primarily stated considering the benefits of a product that combines
prebiotics and probiotics and in which the prebiotic compounds selectively favour the probiotic
strains [109]. Several studies have shown positive synergistic effects for synbiotics on obesity, diabetes,
non-alcoholic fatty liver disease, necrotizing enterocolitis in very low birth weight infants, and in
the treatment of hepatic encephalopathy [110–114]. Despite these findings, few studies have tested
the potential benefits of synbiotics on neurodevelopmental disorders (Table 2). Malaguarnera et al.
reported that B. longum plus FOS improved cognitive function in the treatment of minimal hepatic
encephalopathy (MHE) [107]. Firmansyah et al. provided milk containing synbiotics (BL999, LPR,
and prebiotics) and LCPUFA to 393 healthy toddlers at 12 months-old for 12 months. The authors
reported that the change in cognitive and adaptive behaviour scores between 12 and 16 months was
higher but not significantly different in the synbiotics group compared with the control group [108].
Future work is needed to determine whether synbiotics may contribute to relieve neurological diseases
and to explore the benefits of new potential synbiotics during critical time windows in an infant’s CNS
development and susceptibility to neurological disorders.
7. Future Perspectives
During the last decade, numerous in vivo and in vitro studies have explored the influence of
probiotics and prebiotics in host physiology [115]. Their results showed that gut microbiota may
modulate inflammation, adiposity, satiety, energy expenditure, and glucose metabolism. Most efforts
have focused on studying the mechanisms by which certain probiotics regulate the colonization of
and protect against pathogens through the activation of the mucosal immune system and competition
for limited nutrients [116,117]. Alternate approaches such as recombinant probiotics expressing
therapeutic biomolecules, faecal microbiota transplantation and phage therapy, need be explored for the
manipulation of the gut ecosystem. A proof of concept was the experiment performed by Paton et al.,
where they created a recombinant probiotic by introducing glycosyltransferase genes from Neisseria
meningitidis or Campylobacter jejuni in a harmless Escherichia coli strain (CWG308) to treat and prevent
the diarrheal disease caused by enterotoxigenic E. coli strains [118]. The same group also developed
a recombinant probiotic for the treatment and prevention of cholera [119]. A recent study showed that
microbiota transfer therapy improves ASD symptoms in children, which persists for at least 8 weeks
after the treatment ends [120]. And finally, phage therapy has become an interesting strategy to treat
bacterial infections due to the rise of antibioticresistant microbial strains. The only approved phage
therapy clinical trial in the human gut was carried out in 120 patients with diarrhoea caused by E. coli,
who were infected by a coliphage mix. The treatment failed to solve diarrhoea, although no adverse
effects of phage infection were observed [121]. Customized phage cocktails could be an alternative
for future therapies. These phages would directly target pre-identified bacterial pathogens though
the main drawback would be the high interindividual variation of the gut microbiome and legislative
approval [122,123].
In conclusion, this review summarized the accumulating evidence on the modulation of gut
microbial composition and metabolism as a potential strategy for neurological disorders and CNS
development. Despite this wealth of information, the effect of probiotics and prebiotics is still largely
unexplored, and numerous gaps and inconsistencies exist when the studies are compared. Differences
in quantity of dose, type of strain, type of prebiotic, assessment of gut microbiota, duration of
intervention, standardization of neurological measurements, variety and complexity of neurological
symptoms, study design, and cohort size make it difficult to confirm evidence of efficacy. To this
end, double-blind placebo in vivo studies that exploit the power of the latest robust high-throughput
multi-omic technologies are required to identify the molecular mechanisms of the gut’s microbial
modulation of neurological disorders and CNS development and ultimately to design effective
probiotic and prebiotic therapies.
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